? OVERALL The Fox Chase Cancer Center (FCCC), now in its 51st year as an NCI-designated Comprehensive Cancer Center, has undergone a profound transformation since the time of the last CCSG grant review. In 2012, Fox Chase entered into an affiliation with the Temple University Health System, creating a unique new model that combines the flexibility of a free-standing cancer center with the scientific and clinical breadth of a university- based matrix center. In addition to this organizational change, in 2013, FCCC came under new leadership with the appointment of Richard I. Fisher, MD as President and CEO of FCCC and Cancer Center Director. As a result of these developments, the size and scope of the Cancer Center have greatly expanded, both in terms of its scientific enterprise and also in the number and diversity of the patients served. Cancer-focused, Temple faculty members have been thoroughly integrated into FCCC, adding 54 new CCSG members, including three in leadership positions (Jean-Pierre Issa, MD, PhD, Co-Program Leader for Cancer Epigenetics; Susan Fisher, PhD, Associate Director for Population Science; Grace Ma, PhD, Director of Community Based Research). In addition to expanding membership, the affiliation has enabled access to specialized expertise at Temple University, including the Fels Institute for Cancer Research and Molecular Biology, the Moulder Center for Drug Discovery, and the newly created School of Public Health. Importantly, with the affiliation, FCCC now has greatly enhanced access to an underserved population within its catchment area, surrounding the Temple University Health Science Center in North Philadelphia. Other important accomplishments within the last grant cycle include: a) Recruitment of Wafik El-Deiry, MD, PhD to a new Deputy Directorship for Translational Research to enhance the clinical translation of basic research findings; b) A 40% increase in the direct costs of funded research at FCCC from 2013 - 2015 ($27.7M to $38.7M); c) 43-fold return on investment from CCSG- supported pilot projects; d) Increased accrual to treatment interventional trials, from 358 in 2011 to 668 in 2014 (an 87% increase); e) Establishment of a cutting-edge Research Program in Cancer Epigenetics; and f) Publication of more than 2,200 papers from 2011-2015, with strong intra- and inter-programmatic collaboration, including 20% in journals with Impact Factors > 8, and 11% in journals with Impact Factors > 10. These positive developments demonstrate the renewed strength of FCCC and the importance of its role in the care of cancer patients in this region.

Public Health Relevance

? OVERALL NCI-designated Cancer Centers such as Fox Chase Cancer Center serve as major sources of discovery of the nature of cancer, and development of more effective approaches to prevention, diagnosis and therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006927-51
Application #
9147871
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Shafik, Hasnaa
Project Start
1997-07-01
Project End
2021-07-31
Budget Start
2016-08-12
Budget End
2017-07-31
Support Year
51
Fiscal Year
2016
Total Cost
$2,675,570
Indirect Cost
$1,175,570
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Reese, Jennifer Barsky; Bober, Sharon L; Daly, Mary B (2017) Talking about women's sexual health after cancer: Why is it so hard to move the needle? Cancer 123:4757-4763
Peri, Suraj; Caretti, Elena; Tricarico, Rossella et al. (2017) Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget 8:17628-17642
Jiang, Pengtao; Li, Yueran; Poleshko, Andrey et al. (2017) The Protein Encoded by the CCDC170 Breast Cancer Gene Functions to Organize the Golgi-Microtubule Network. EBioMedicine 22:28-43
Christian, Allison H; O'Malley, Denalee; Barac, Ana et al. (2017) Cardiovascular risk and communication among early stage breast cancer survivors. Patient Educ Couns 100:1360-1366
Heckman, Carolyn J; Kloss, Jacqueline D; Feskanich, Diane et al. (2017) Associations among rotating night shift work, sleep and skin cancer in Nurses' Health Study II participants. Occup Environ Med 74:169-175
Stepanova, Dina S; Semenova, Galina; Kuo, Yin-Ming et al. (2017) An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Res 77:5026-5038
Gerson, James N; Skariah, Sam; Denlinger, Crystal S et al. (2017) Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs 26:531-540
Cheung, Mitchell; Testa, Joseph R (2017) BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res 6:270-278
Kruger, Warren D (2017) Cystathionine ?-synthase deficiency: Of mice and men. Mol Genet Metab 121:199-205
Jaffe, Eileen K (2017) New protein structures provide an updated understanding of phenylketonuria. Mol Genet Metab 121:289-296

Showing the most recent 10 out of 1165 publications